Research

The “Autonomous AI for Cancer Detection” project is supported by the European Fund for Regional Development and brings together ScreenPoint Medical, Radboud University Medical Center (Radboud UMC), and Thirona. Together, these partners are developing AI tools to support the early detection of breast and lung cancer, aiming to improve clinical outcomes and streamline diagnostic workflows.

The project focuses on creating AI systems that can operate semi-autonomously—safely assisting or even performing parts of diagnostic tasks. For breast cancer screening, ScreenPoint and Radboud UMC are developing and validating solutions that can automatically identify normal mammograms, reducing radiologist workload while maintaining patient safety. These tools are designed to minimize false negatives and include built-in quality controls that enable human oversight when needed.

For lung cancer detection, Thirona and Radboud UMC are building AI-assisted tools to guide lung biopsies, particularly for targeting small, suspicious nodules with greater accuracy and efficiency.

In addition to technological development, the project also examines regulatory requirements and gathers input from key stakeholders to ensure the AI solutions are ethically sound, clinically acceptable, and ready for real-world application.

Project runtime: Jan 2025 – End of 2027.